To the best of our knowledge, there are currently no reports on whether sSS or anti-Ro/SS-A antibodies influence the pharmacological dynamics, therapeutic effects, or development of LPD in patients with RA treated with TNFis other than IFX, ETN, and adalimumab (ADA). The gene discussed is CALR; the disease is disseminated peritoneal leiomyomatosis.